Navigation Links
Cell Biosciences Announces New Leadership

PALO ALTO, Calif., June 25 /PRNewswire/ -- Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three important additions to its management team.

Tim Harkness was named President and Chief Executive Officer. From 1998 through 2007, Mr. Harkness was the Chief Financial Officer for Molecular Devices Corporation where he helped build the company into a global leader in life science research tools with over $185 million in revenue before successfully selling the company in 2007. Mr. Harkness brings deep knowledge of worldwide life sciences markets, and is expected to lead the transformation of Cell Biosciences into a mature commercial operation.

Richard Lussier was named Vice President, Sales and International Operations. Mr. Lussier has more than 20 years experience in life science sales and commercial operations, including 13 years in the Applera businesses Applied Biosystems and Celera Genomics. During his tenure at Applera, he served as President and General Manager of their Japanese subsidiary for five years. More recently, Mr. Lussier established the worldwide sales, service, and support organization for Solexa Inc., now part of Illumina Inc.

Also announced was the appointment of Walter Ausserer, Ph.D. as Vice President, Marketing. Dr. Ausserer has more than 15 years experience in the development, sales, and marketing of bioanalytical instrumentation. Most recently, he directed product development at Axela Biosensors, a developer of label-free protein characterization systems. Dr. Ausserer previously held senior product development and marketing positions at Caliper Life Sciences and Dionex Corporation.

"The Cell Biosciences team has developed a truly revolutionary technology for protein characterization that I believe has the potential to significantly impact many areas of biological research," said Mr. Harkness. "I am impressed by the tremendous potential of the Cell Biosciences team and technology, and am very excited about the opportunity to lead the company."

The management team appointments come on the heels of multiple recent placements of the Firefly(TM) 3000 system, Cell Bioscience's flagship product for ultrasensitive detection and characterization of proteins in extremely small biological samples. Cell Biosciences began accepting orders for the Firefly 3000 system in late 2007 as part of an early technology access program for leading cell signaling and translational medicine researchers. Participants in the program receive early access to the Firefly 3000 system, which provides unprecedented levels of sensitivity for the analysis of precious samples, such as tissue biopsies, fine-needle tumor aspirates, and stem cells.

To fuel its commercial expansion, the company closed a Series B financing round of $27 million in late 2006, with participation from the Wellcome Trust, Domain Associates, Latterell Venture Partners, Novo Ventures, Posco BioVentures, Mitsui & Co. Venture Partners, RBC Capital Partners and The Vertical Group.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection of specific proteins in extremely small biological samples. The company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA.

For additional information, please contact Walter Ausserer, Vice President, Marketing, Cell Biosciences, Inc. 650 859-1485.

SOURCE Cell Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

2. LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. LI-COR Biosciences Introduces Near-Infrared Small Animal Imager
5. Craig Johnson Joins Ardea Biosciences Board of Directors
6. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
7. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
8. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
10. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
11. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):